Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | JAK3 | P52333 | 11/20 | 0.40 |
| ▸ | BTK | Q06187 | 5/20 | 0.40 |
| ▸ | EGFR | P00533 | 3/20 | 0.40 |
| ▸ | JAK1 | P23458 | 2/20 | 0.40 |
| ▸ | JAK2 | O60674 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30208798 | 1.00 | CA12 (0.47) | CA12CA1CA2CA9JAK3 | |
| SCHEMBL8362428 | 1.00 | CA12 (0.47) | CA12CA1CA2CA9JAK3 | |
| SCHEMBL20893428 | 0.88 | DPP4 (0.40) | JAK3JAK1JAK2 | |
| SCHEMBL13451855 | 0.88 | DPP4 (0.40) | JAK3JAK1JAK2 | |
| SCHEMBL18615557 | 0.88 | DPP4 (0.40) | JAK3JAK1JAK2 | |
| SCHEMBL18173568 | 0.81 | JAK3 (0.44) | JAK3BTKEGFRJAK1JAK2 | |
| SCHEMBL18173596 | 0.81 | JAK3 (0.44) | JAK3BTKEGFRJAK1JAK2 | |
| SCHEMBL24113542 | 0.79 | JAK3 (0.43) | JAK3BTKEGFRJAK1JAK2 | |
| SCHEMBL22296413 | 0.79 | JAK3 (0.41) | JAK3BTKEGFRJAK1JAK2 | |
| SCHEMBL16123340 | 0.79 | JAK3 (0.42) | JAK3BTKEGFRJAK1JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113583001-A | Preparation of ibrutinib | 江苏君若药业有限公司 | 2021-11-02 | — | — | CN | claimed |
| US-20250161304-A1 | Methods for Treating Cancer Using Pyrimidine and Pyridine Compounds with BTK Inhibitory Activity | MERCK PATENT GMBH (DE) | 2025-05-22 | — | — | US | disclosed |
| US-11491153-B2 | Methods for treating cancer using pyrimidine and pyridine compounds with BTK inhibitory activity | MERCK PATENT GMBH (DE) | 2022-11-08 | — | — | US | disclosed |
| CN-113583001-A | Preparation of ibrutinib | 江苏君若药业有限公司 | 2021-11-02 | — | — | CN | disclosed |
| CN-113583001-A | Preparation of ibrutinib | 江苏君若药业有限公司 | 2021-11-02 | — | — | CN | disclosed |
| US-10435409-B2 | Process for the preparation of ibrutinib | SHILPA MEDICARE LIMITED | 2019-10-08 | — | — | US | disclosed |
| US-20190040069-A1 | PROCESS FOR THE PREPARATION OF IBRUTINIB | SHILPA MEDICARE LIMITED (IN) | 2019-02-07 | — | — | US | disclosed |
| EP-3077395-B1 | PYRROLO[2,3-D]PYRIMIDINYL, PYRROLO[2,3-B]PYRAZINYL AND PYRROLO[2,3-D]PYRIDINYL ACRYLAMIDES | PFIZER (US) | 2017-11-15 | — | — | EP | disclosed |
| WO-2017134588-A1 | PROCESS FOR THE PREPARATION OF IBRUTINIB | SHILPA MEDICARE LIMITED (IN) | 2017-08-10 | — | — | WO | disclosed |
| WO-2015083028-A1 | PYRROLO[2,3-D]PYRIMIDINYL, PYRROLO[2,3-B]PYRAZINYL AND PYRROLO[2,3-D]PYRIDINYL ACRYLAMIDES | PFIZER INC. (US) | 2015-06-11 | — | — | WO | disclosed |
| CN-104557946-A | Preparation method of ibrutinib | WANG LIQIANG | 2015-04-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190040069-A1 | PROCESS FOR THE PREPARATION OF IBRUTINIB | BTK, SYK, JAK1 | CA12 4729/4885CA1 4847/4885CA2 4569/4885 |
| US-20250161304-A1 | Methods for Treating Cancer Using Pyrimidine and Pyridine Compounds with BTK Inhibitory Activity | BTK, SYK, LCK | CA12 4792/4885CA1 4818/4885CA2 3179/4885 |
| US-11491153-B2 | Methods for treating cancer using pyrimidine and pyridine compounds with BTK inhibitory activity | BTK, SYK, LCK | CA12 4792/4885CA1 4818/4885CA2 3179/4885 |
| US-10435409-B2 | Process for the preparation of ibrutinib | BTK, SYK, JAK1 | CA12 4760/4885CA1 4850/4885CA2 4555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.